Methylin

(methylphenidate)

Forms/Strengths

• Liquid (grape flavored): 5 mg/5 mL, 10 mg/5 mL
• Chewable: 2.5 mg, 5 mg, 10 mg

Dosing

• Age: ≥ 6 y/o
• Onset: ~20-60 min
• Duration: 3-4 hours
• Considerations: Typically dosed multiple times per day. May be taken with or without food.
  • Liquid: Colorless, grape-flavored liquid; store at room temperature. 
  • Chewable: Grape-flavored chewable tablet.
• Initial Dose: 5 mg twice daily (before breakfast and lunch)
• Titration: 5-10 mg weekly
• Max Dose: 2mg/kg/day up to 60 mg/day
  

Quick Facts

• Blocks dopamine/norepinephrine reuptake; enhances focus, attention, and impulse control
• Immediate-release formulation provides rapid onset
• Available as tablets and oral solution
• Common side effects: decreased appetite, insomnia, headache, stomach upset

Indications

•  ADHD (ICD-10: F90.0)
• Narcolepsy: G47.419

Off-Label Uses

• Binge Eating Disorder (F50.2) – Sometimes used to help curb compulsive overeating
• Treatment-Resistant Depression (F33.9) – May improve motivation and energy in certain cases
• Cancer-related Fatigue (R53.0) – Can enhance alertness and reduce severe fatigue
• Other Fatigue Syndromes (R53.83) – May help improve wakefulness in chronic fatigue

How to Take

• Administer orally, preferably 30 to 45 minutes before meals.
• Take two to three times daily, as directed, with doses at least 4 hours apart.
• Can be taken with or without food; high-fat meals may delay absorption.
• Swallow the tablet whole; do not crush or chew.
• If using the oral solution, measure dose carefully with a provided dosing syringe or cup—do not use household spoons.
• Avoid taking late in the day to prevent insomnia.

Side Effects

• Common: Insomnia, decreased appetite, headache, abdominal pain, tachycardia, dry mouth
• Serious: Cardiovascular events (e.g., sudden death in patients with cardiac abnormalities), psychiatric events (e.g., psychosis, mania), priapism, growth suppression in children

Monitoring / Labs

• Cardiovascular: Baseline and routine monitoring of heart rate and blood pressure.
• Growth in Pediatrics: Regular monitoring of height and weight to detect growth suppression.
• Psychiatric Symptoms: Observe for mood changes, anxiety, or psychosis.
• Abuse Potential: Monitor for misuse or diversion.

Education

• When to Call the Doctor:

  • Severe mood changes, aggression, or suicidal thoughts.
  • Chest pain, rapid heartbeat, shortness of breath (cardiovascular concerns).
  • Uncontrolled movements, tics, or worsening anxiety.
  • Numbness, coldness, or color changes in fingers or toes (circulatory issues).
  • Unexplained weight loss or delayed growth in pediatric patients.

• Safety Tips:

  • Monitor blood pressure and heart rate, especially in patients with cardiovascular risk.
  • Use caution in patients with anxiety, bipolar disorder, or psychosis, as symptoms may worsen.
  • Avoid caffeine and other stimulants, which may amplify side effects.
  • Ensure adequate hydration and nutrition, as appetite suppression is common.
  • Tapering may be required if discontinuing after long-term use.

• Parent Tips for Pediatric Patients:

  • Encourage a nutrient-dense diet to counteract appetite suppression.
  • Administer in the morning before school for optimal effect.
  • Monitor school performance and behavioral changes.
  • Observe for sleep disturbances; adjust timing if necessary.
  • Communicate regularly with teachers and caregivers about medication effects.

Additional Information

• Contraindications:

  • Hypersensitivity to methylphenidate or formulation components.
  • Use within 14 days of MAOI therapy (risk of hypertensive crisis).
  • Symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma.
  • History of substance use disorder, unless benefits outweigh risks.

• Pregnancy:

  • Category C; use only if benefits outweigh risks.
  • May cause neonatal withdrawal symptoms or low birth weight.

• Lactation:

  • Excreted in breast milk; not recommended due to potential infant exposure.

• Drug Interactions:

  • Serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs) increase serotonin syndrome risk.
  • Acidifying agents (e.g., ascorbic acid) may reduce drug absorption.
  • Alkalinizing agents (e.g., sodium bicarbonate) may increase methylphenidate levels.
  • May potentiate hypertensive effects of certain medications (e.g., decongestants, beta-agonists).